Euroapi SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David Seignolle
- Full Time Employees
- 3,133
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 32 rue Alexandre Dumas Paris IF France 75011
- IPO Date
- May 6, 2022
- Website
- euroapi.com
- Similar Companies
- Business
- Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients (APIs) and intermediates used in the formulation of medicines for human and veterinary use. The company offers an extensive portfolio of approximately 200 products, including vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates such as morphine, codeine and thebaine, analgesics, lipids, and various small molecules. Euroapi also provides contract development and manufacturing organization (CDMO) services, specializing in custom development and manufacturing of APIs and advanced technologies such as particle engineering, microbial fermentation, solid phase chemistry, and drug delivery solutions. Its CDMO capabilities include GMP-compliant scale-up, route scouting, process development, full analytical support, and regulatory assistance predominantly for pharmaceutical and biotech companies. Founded in 2020 and headquartered in Paris, France, Euroapi operates six production sites across Europe, including France, the United Kingdom, Germany, Italy, and Hungary. The company primarily serves pharmaceutical originator companies, generic drug manufacturers, animal health product firms, consumer health and nutrition companies, and cosmetic product companies, targeting global healthcare markets. Recently, Euroapi launched its FOCUS-27 strategic plan, a four-year initiative aimed at enhancing competitiveness, operational efficiency, and sustainable profitable growth. In 2024, Euroapi accelerated its efforts under this plan with initiatives to streamline operations, increase agility, and improve industrial and procurement efficiencies. Notably, in 2024, Euroapi secured a five-year development and manufacturing agreement with Priothera, a biotech company specialized in hematological malignancies and CAR-T cell therapies. The company also expanded its CDMO portfolio by launching 14 new projects during the first half of 2024, including contributions to mRNA vaccine platforms involving lipid nanoparticle development. Additionally, Euroapi amended its commercial agreement with Sanofi to further stabilize its operational framework. These recent moves signify Euroapi’s strategic focus on innovation, diversification beyond its historical reliance on Sanofi, and strengthening Europe’s healthcare sovereignty. Euroapi has about 3,450 employees and continues to invest in R&D and advanced pharmaceutical manufacturing technologies to support pharmaceutical innovation globally. Its comprehensive product range, combined with CDMO services and recent strategic partnerships, positions Euroapi as a leading European player in the active pharmaceutical ingredients industry. This description reflects Euroapi’s current operations, extensive product and service portfolio, and significant recent strategic developments through 2024 and early 2025.
Company News
Medisca and EUROAPI Form Strategic Partnership to Strengthen API Access for Pharmaceutical Compounding
Euroapi S.A. (EAPIF) Q2 2026 Earnings Call Transcript
EUROAPI statement regarding the Brindisi site
EUROAPI - Availability of the 2025 Universal Registration Document
Euroapi S.A. (EAPIF) Q4 2025 Earnings Call Transcript
Euroapi S.A. (OTCMKTS:EAPIF) Short Interest Update
Abolis Biotechnologies and EUROAPI Enter Into Partnership to Accelerate Pharmaceutical Innovation and Restore European Sovereignty
With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of health sovereignty
Science Based Targets initiative (SBTi) validates EUROAPI's near-term climate targets
Euroapi: Public Financing, Reorganization, And Very Cheap
EUROAPI sells Haverhill site to Particle Dynamics as part of its FOCUS-27 transformation plan
Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities
EUROAPI moves into a new chapter with new Governance and Leadership
Olivier Falut appointed EUROAPI's Chief Financial Officer
EUROAPI closes the financing of its FOCUS-27 plan
EUROAPI completes the financing of its FOCUS-27 plan and moves forward with its execution
Aizon Launches New AI-powered eBR Light Solution to Enhance Manufacturing Productivity in Collaboration with Euroapi
EUROAPI - Availability of 2024 Half-Year Financial Report
EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth1
EUROAPI and Priothera enter into CDMO collaboration to advance oncology project